| 2023-ISAA-70121 | |
| Researchers at Purdue University have developed a novel photosensitizer as a chemotherapeutic against triple negative breast cancer (TNBC). TNBC is the most prevalent form of cancer found in women and is considered the most aggressive form of breast cancer, comprising 15-20% of breast cancer cases. Current standard treatment for TNBC utilizes traditional chemotherapies. Unfortunately, traditional chemotherapies have high toxicity and often result in cancers with drug resistance. This has led to a dire need to discover novel treatments. Purdue researchers have developed photosensitizers as a co-therapy with current chemotherapies. These compounds at 100 nanomolar were able to generate synergistic activity against TNBC cells with Taxol, Cisplatin, Fluorouracil, or Methotrexate. Furthermore, researchers discovered that the mode of action for the death of TNBC cells is mitotic catastrophe with slight autophagy. Combinational therapy with these photosensitizers not only shows a decrease in cell viability but the dosage of the chemotherapeutic is also reduced. Technology Validation: This technology has been validated using a transmission electron microscope, fluorescence microscopy, and MTT assay. These methods demonstrated that the novel photosensitizer works synergistically with known chemotherapeutics and identified the mode of cell death. Advantages: -Known mechanism of death -Reduced chemotherapy dosage -Sensitize cancer cells to known chemotherapeutics Applications: -Triple negative breast cancer -Chemotherapeutic -Cancer therapy Publication: Chlorin Conjugates in Photodynamic Chemotherapy for Triple-Negative Breast Cancer DOI: https://doi.org/10.21203/rs.3.rs-2894973/v1 |
|
|
|
|
May 5, 2023
Provisional-Patent
United States
(None)
(None)
|
|
|
Purdue Office of Technology Commercialization The Convergence Center 101 Foundry Drive, Suite 2500 West Lafayette, IN 47906 Phone: (765) 588-3475 Fax: (765) 463-3486 Email: otcip@prf.org |
